Medicare AdvantageCoverageMedium impact
MA08.009y, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Independence Blue Cross·Allergy & Immunology, Hematology, Oncology +2 more·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.009y for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) has been updated with an effective date of April 1, 2026. This policy change affects billing and coverage requirements for immunoglobulin therapies under Medicare Advantage plans.
Action Required
Before April 1, 2026: Billing team must review the complete policy MA08.009y at the provided URL to understand specific changes to IVIG/SCIG coverage requirements. Update billing procedures and prior authorization workflows for immunoglobulin therapies for Medicare Advantage patients. Ensure staff are trained on any new documentation or coverage criteria.